Clinical Trial Update: A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the safety and effectiveness of risperidone for conduct disorder and other disruptive behavior disorders in children aged 5 to 12 with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Conduct Disorder
• Disruptive Behavior Disorder
• Oppositional Defiant Disorder

Drugs mentioned

• RISPERIDONE (RISPERIDONE)

Snippet

Sponsor: Janssen Pharmaceutica N.V., Belgium | Conditions: Conduct Disorder, Oppositional Defiant Disorder | Phase 3 | Status: COMPLETED